Tizanidine
| Clinical data | |
|---|---|
| Pronunciation | /taɪˈzænɪdiːn/ tye-ZAN-i-deen |
| Trade names | Zanaflex, Sirdalud, and others |
| Other names | AN-021; DS 103-282 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601121 |
| License data |
|
| Routes of administration | Oral (tablets, capsules) |
| Drug class | α2-Adrenergic receptor agonist; Muscle relaxant; Sedative; Hypnotic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~40% |
| Protein binding | ~30% |
| Metabolism | Extensive (>95%), primarily via CYP1A2 |
| Elimination half-life | Tizanidine: 2.5 hours Inactive metabolites: 20–40 hours |
| Excretion | Urine (60%), feces (20%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.125.400 |
| Chemical and physical data | |
| Formula | C9H8ClN5S |
| Molar mass | 253.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tizanidine, sold under the brand names Zanaflex and Sirdalud among others, is an α2-adrenergic receptor agonist and muscle relaxant which is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Its effectiveness appears to be similar to that of other muscle relaxants like baclofen or diazepam. The drug is taken orally.
Common side effects of tizanidine include sleepiness, dry mouth, asthenia, dizziness, low blood pressure, and low heart rate. Serious side effects may include dangerously low blood pressure, liver problems, and psychosis. It is unclear if use in pregnancy and breastfeeding is safe. The drug is an α2-adrenergic receptor agonist, but how it works is not entirely clear.
Tizanidine was approved for medical use in the United States in 1996. It is available as a generic medication. In 2023, it was the 81st most commonly prescribed medication in the United States, with more than 8 million prescriptions.